Advancing drug discovery for schizophrenia

Stephen R. Marder, Bryan Roth, Patrick F. Sullivan, Edward M. Scolnick, Eric J. Nestler, Mark A. Geyer, Daniel R. Welnberger, Maria Karayiorgou, Alessandro Guidotti, Jay Gingrich, Schahram Akbarian, Robert W. Buchanan, Jeffrey A. Lieberman, P. Jeffrey Conn, Stephen J. Haggarty, Amanda J. Law, Brian Campbell, John H. Krystal, Bita Moghaddam, Akira Saw & 4 others Marc G. Caron, Susan R. George, John Allen, Michelle Solis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

Original languageEnglish (US)
Pages (from-to)30-43
Number of pages14
JournalAnnals of the New York Academy of Sciences
Volume1236
Issue number1
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Drug Discovery
Schizophrenia
Genes
Health
National Institute of Mental Health (U.S.)
Biomedical Technology
Molecules
Translational Medical Research
Epigenomics
Pharmaceutical Preparations
Drugs
Research
Therapeutics

Keywords

  • Genetics
  • GWAS
  • Neuronal function
  • Schizophrenia
  • Small molecules
  • Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., ... Solis, M. (2011). Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences, 1236(1), 30-43. https://doi.org/10.1111/j.1749-6632.2011.06216.x

Advancing drug discovery for schizophrenia. / Marder, Stephen R.; Roth, Bryan; Sullivan, Patrick F.; Scolnick, Edward M.; Nestler, Eric J.; Geyer, Mark A.; Welnberger, Daniel R.; Karayiorgou, Maria; Guidotti, Alessandro; Gingrich, Jay; Akbarian, Schahram; Buchanan, Robert W.; Lieberman, Jeffrey A.; Conn, P. Jeffrey; Haggarty, Stephen J.; Law, Amanda J.; Campbell, Brian; Krystal, John H.; Moghaddam, Bita; Saw, Akira; Caron, Marc G.; George, Susan R.; Allen, John; Solis, Michelle.

In: Annals of the New York Academy of Sciences, Vol. 1236, No. 1, 10.2011, p. 30-43.

Research output: Contribution to journalArticle

Marder, SR, Roth, B, Sullivan, PF, Scolnick, EM, Nestler, EJ, Geyer, MA, Welnberger, DR, Karayiorgou, M, Guidotti, A, Gingrich, J, Akbarian, S, Buchanan, RW, Lieberman, JA, Conn, PJ, Haggarty, SJ, Law, AJ, Campbell, B, Krystal, JH, Moghaddam, B, Saw, A, Caron, MG, George, SR, Allen, J & Solis, M 2011, 'Advancing drug discovery for schizophrenia', Annals of the New York Academy of Sciences, vol. 1236, no. 1, pp. 30-43. https://doi.org/10.1111/j.1749-6632.2011.06216.x
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 2011 Oct;1236(1):30-43. https://doi.org/10.1111/j.1749-6632.2011.06216.x
Marder, Stephen R. ; Roth, Bryan ; Sullivan, Patrick F. ; Scolnick, Edward M. ; Nestler, Eric J. ; Geyer, Mark A. ; Welnberger, Daniel R. ; Karayiorgou, Maria ; Guidotti, Alessandro ; Gingrich, Jay ; Akbarian, Schahram ; Buchanan, Robert W. ; Lieberman, Jeffrey A. ; Conn, P. Jeffrey ; Haggarty, Stephen J. ; Law, Amanda J. ; Campbell, Brian ; Krystal, John H. ; Moghaddam, Bita ; Saw, Akira ; Caron, Marc G. ; George, Susan R. ; Allen, John ; Solis, Michelle. / Advancing drug discovery for schizophrenia. In: Annals of the New York Academy of Sciences. 2011 ; Vol. 1236, No. 1. pp. 30-43.
@article{a6f623cc0d164cc3b930110d92127f7e,
title = "Advancing drug discovery for schizophrenia",
abstract = "Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, {"}Advancing Drug Discovery for Schizophrenia{"} was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.",
keywords = "Genetics, GWAS, Neuronal function, Schizophrenia, Small molecules, Therapeutics",
author = "Marder, {Stephen R.} and Bryan Roth and Sullivan, {Patrick F.} and Scolnick, {Edward M.} and Nestler, {Eric J.} and Geyer, {Mark A.} and Welnberger, {Daniel R.} and Maria Karayiorgou and Alessandro Guidotti and Jay Gingrich and Schahram Akbarian and Buchanan, {Robert W.} and Lieberman, {Jeffrey A.} and Conn, {P. Jeffrey} and Haggarty, {Stephen J.} and Law, {Amanda J.} and Brian Campbell and Krystal, {John H.} and Bita Moghaddam and Akira Saw and Caron, {Marc G.} and George, {Susan R.} and John Allen and Michelle Solis",
year = "2011",
month = "10",
doi = "10.1111/j.1749-6632.2011.06216.x",
language = "English (US)",
volume = "1236",
pages = "30--43",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Advancing drug discovery for schizophrenia

AU - Marder, Stephen R.

AU - Roth, Bryan

AU - Sullivan, Patrick F.

AU - Scolnick, Edward M.

AU - Nestler, Eric J.

AU - Geyer, Mark A.

AU - Welnberger, Daniel R.

AU - Karayiorgou, Maria

AU - Guidotti, Alessandro

AU - Gingrich, Jay

AU - Akbarian, Schahram

AU - Buchanan, Robert W.

AU - Lieberman, Jeffrey A.

AU - Conn, P. Jeffrey

AU - Haggarty, Stephen J.

AU - Law, Amanda J.

AU - Campbell, Brian

AU - Krystal, John H.

AU - Moghaddam, Bita

AU - Saw, Akira

AU - Caron, Marc G.

AU - George, Susan R.

AU - Allen, John

AU - Solis, Michelle

PY - 2011/10

Y1 - 2011/10

N2 - Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

AB - Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

KW - Genetics

KW - GWAS

KW - Neuronal function

KW - Schizophrenia

KW - Small molecules

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=80055004719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055004719&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2011.06216.x

DO - 10.1111/j.1749-6632.2011.06216.x

M3 - Article

VL - 1236

SP - 30

EP - 43

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -